ISSWSH Press Release

PRESS RELEASE
 
Reference Articles:
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women A Systematic Review and Meta-Analysis, Loes Jaspers; Frederik Feys; Wichor M. Bramer; Oscar H. Franco; Peter Leusink; Ellen T. M. Laan; JAMA Intern Med. doi:10.1001/jamainternmed.2015.8565, Published online February 29, 2016.
and the accompanying editorial
US Food and Drug Administration Approval of Flibanserin, Even the Score Does Not Add Up, Steven Woloshin; Lisa M. Schwartz; JAMA Internal Medicine Published online February 29, 2016.

Download PDF
- Press Release
- Bullet Points Reference Article
- Bullet Points Accompanying Editorial

February 29, 2016 -
Science has been corrupted by bias and personal agendas resulting in publication of a distorted analysis of outcomes of research trials. As authorities in the area of sexual function and dysfunction in women, in particular hypoactive sexual desire disorder (HSDD), the Board of Directors of the International Society for the Study of Women's Sexual Health (ISSWSH)1 is concerned that the aforementioned articles would be accepted by and published as quality science and factual commentary. According to Levine, the diverse controversies involving treatments for sexual difficulties have resulted in stakeholders interpreting science for us in ways that support their political ideological views, economic interests, or skill sets.2 This is clearly the case with regard to both the Jaspers et al. article and subsequent editorial response. We wish to set the record straight. When articles that reflect opinion rather than science are published in scientific journals, they harm those meant to be aided by science and medicine resulting, in this case, in a great disservice to the millions of pre-menopausal women suffering from HSDD.

Read more: ISSWSH Press Release


Scientific Program of the ISSWSH Annual Meeting 2016

We're excited to announce the availability of our full and detailed scientific program for the upcoming Annual Meeting to be held in Charleston, South Carolina, from February 25 to 28, 2016. For full details please visit http://www.isswshmeeting.org today. While you're there, please don't forget to register! See you in Charleston

2015 Consensus terminology and classification of persistent vulvar pain

Dear ISSWSH Members

Since the previous terminology of vulvodynia was accepted by the International Society for the Study of Vulvovaginal Disorders (ISSVD) in 2003, studies have explored possible causative factors and treatment options. The International Society for the Study of Women's Sexual Health (ISSWSH), The International Society for the Study of Vulvovaginal Disorders (ISSVD) and the International Pelvic Pain Society (IPPS) believed there was an unmet medical need for a comprehensive, evidence-based set of vulvovaginal pain diagnoses that can be easily utilized by both expert and non-expert healthcare providers to establish diagnoses in their patients and to guide treatment. Therefore we discussed the possibility of revision of 2003 terminology and organized an ISSWSH sponsored international meeting in order to reach a consensus on the terminology of vulvar pain, April 8 - 9, 2015 in Annapolis, Maryland. The American College of Obstetricians and Gynecologists (ACOG) and the National Vulvodynia Association (NVA) were also represented.

Read more: 2015 Consensus terminology and classification of...


Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from hypoactive sexual desire disorder

Dear ISSWSH members,

It is with tremendous excitement that we share the announcement that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose members voted 18-6 for approval.

Read more: Flibanserin approved as the FIRST pharmacologic...


General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

Read more: General Statement of the International Society...


FDA announced a Public Advisory Committee Meeting

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link. - -


Information about the ISSWSH Business Meeting

The ISSWSH Business Meeting will take place in the Capitol Ballroom A-D of the Sheraton Austin Hotel at the Capitol in Austin, TX on Friday February 20, 2015. The meeting is scheduled for 60 minutes from 5:00 - 6:00 pm.

Save the Date

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Visit the Course Website

ISSWSH Annual Meeting 2021
March 5-7, 2021   96 days left
Virtual
Visit the Meeting Website

ISSWSH Fall Course 2021
October 7-10, 2021   313 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

Latest Tweets

The (Sexual) Rise of a Nation-India and the emerging sex toy market https://t.co/lIl7VzWdkg ISSWSH
Big News! The abstract submission deadline for the 2021 Virtual Annual Meeting has been extended to December 6! Don… https://t.co/UjXikGFQpx ISSWSH
Dont forget the Vulva! Impact of vulvovaginal atrophy on sexual function in postmenopausal women https://t.co/tTPFAy0ygu ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram